General Information
Executive Board
Prof. Dr. H. Crijns (Leader Main Theme II), R. van der Zander, Finance Director,
Prof. Dr. T. Hackeng (Leader Main Theme I), Prof. Dr. M. Post (Leader Main Theme III)
Dr P. Uittenbogaard
Prof. Dr. M. Daemen, Scientific Director CARIM.
Dr. A. Duijvestijn, Education Program coordinator since January 1, 2009. Telephone number 043-3881431/1433. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Drs. P. Uittenbogaard, Project manager, since April 1, 2009. Telephone number 043-3881131. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Prof. Dr. J. Rosing till May 1, 2009 and Dr. T. Hackeng, Leader Main Theme 1, since May 1, 2009
top
Background of CARIM
The importance of the subject for public health is obvious. Cardiovascular disorders, often caused by atherosclerosis, are at the root of a large number of serious diseases, and cause about half of all mortalities. Since it would be impossible to study all aspects of cardiovascular diseases, CARIM has set priorities for the main lines of research, based on the available expertise and the relevance for health care. Three main areas of research can be distinguished within the institute:
1. research focusing on thrombosis and hemostasis. These research activities are largely concentrated in 4 programs;
2. research on the functioning of the normal and failing heart, and on the possibilities for detecting and treating high risk cardiac patients. These research activities are concentrated in 5 programs.
3. research focusing on vascular biology of both large and small vessels.
These research activities are also concentrated in 5 programs. Each program is led by one to three principal investigators (PI's). The PI's are responsible for the scientific progress of their program, the mentoring of their PhD-students and post-docs and the financial basis of their program.
All three themes of research involve fundamental as well as clinical studies. The institute has expertise in a wide range of areas, ranging from molecular biology to population-based studies. Its goal is to focus on clinically important questions, integrating knowledge from molecule to patient. Activities within the three main areas of research are not isolated entities, since close cooperation exists both between and within the main research areas. The research areas within CARIM are depicted schematically in the figure below. top
Overview of Research Areas
|
|
|
||||||||||||||
|
|
|
|
sub themes |
|
programmes |
|
|
|
|
||||||
|
|
|
A |
|
Structure and function of coagulation factors |
Pathophysiology of thrombin formation |
Regulation of thrombin formation by antithrombotic drugs |
FXa and thrombin formation at macroscopic surfaces |
|
|||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
B |
|
Signal transduction in platelets and endothelial cells |
Mechanism and regulation of procoagulant cell surfaces |
Lupus anticoagulants and "antiphospholipid syndrome" |
|||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
C |
|
Vit K-dependent carboxylase enzyme-substrate interactions |
Uptake and biological availability of K-vitamins |
Role of Vit K-dependent proteins in atherosclerosis |
Annexin V: apoptosis, thrombosis and atherosclerosis |
|
|||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
D |
|
Pathophysiology of arterial thrombosis |
Blood coagulation and organ failure |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
||||||||||||||
|
|
|
|
sub themes |
|
programmes |
|
|
|
|
||||||
|
|
|
A |
|
Acute ischemic cardiac injury |
Prevention and treatment of post-operative myocardial ischemia |
Programmed cell survival and cell death |
Functional adaptation and wound healing and tissue adaptation after myocardial infarction |
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
B |
|
Disturbances in the regulation of cardiac substrate uptake and utilization |
Genetic control of cardiac metabolism |
Disturbed myocardial energy metabolism and calcium homeostasis |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
C |
|
Mechanical heterogeneties and dysfunction in the intact heart |
Mechanical dysfunction in cardiac cells |
Non-pharmacological interventions and devices in heart failure |
Clinical approach to cardiac failure |
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
D |
|
Pathophysiological mechanisms of atrial fibrillation |
Ventricular arrhythmias |
Clinical aspects of cardiac arrhythmias |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
E |
|
Cardiovascular genetics and genomics |
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
||||||||||||||
|
|
|
|
sub themes |
|
programmes |
|
|
|
|
||||||
|
|
|
A |
|
Angiogenesis |
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
B |
|
Non invasive assessment of human vascular function |
Experimental vascular remodelling |
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
C |
|
Predisposition to disturbances in the circulation and therapeutic interventions |
Predisposition to insulin resistance/familial combined hyperlipidemia/diabetes mellitus |
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
D |
|
Microvascular aspects of vascular occlusion |
Atherogenesis and inflammation |
The instabile atherosclerotic plaque |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
E |
|
Clinical vascular medicine |
Occlusive vascular disease |
Imaging of vascular disease |
Vascular growth |
||||||||
|
|
|
|
|
|
|
|
|
|
|||||||